用依维莫司治疗的伴有多发转移的侵袭性卵巢神经内分泌肿瘤：一例报告
Aggressive neuroendocrine tumor of the ovary with multiple metastases treated with everolimus: A case report.
作者信息
Kaiho-Sakuma Michiko, Toyoshima Masafumi, Watanabe Mika, Toki Asami, Kameda Satomi, Minato Takamichi, Niikura Hitoshi, Yaegashi Nobuo
机构信息
Department of Obstetrics and Gynecology, Tohoku University Hospital, Sendai, Japan.
Department of Pathology, Tohoku University Hospital, Sendai, Japan.
出版信息
Gynecol Oncol Rep. 2018 Jan 4;23:20-23. doi: 10.1016/j.gore.2018.01.002. eCollection 2018 Feb.
Abstract
•Neuroendocrine tumors (NETs) frequently occur in the lungs or the gastrointestinal tract; they are uncommon in the ovary.•The mammalian target of rapamycin (mTOR) pathway has been reported as a treatment for advanced NETs.•We describe a patient with an aggressive primary ovarian NET, successfully treated with everolimus (an mTOR inhibitor).
摘要
•神经内分泌肿瘤（NETs）常发生于肺部或胃肠道；在卵巢中较为罕见。
•哺乳动物雷帕霉素靶蛋白（mTOR）通路已被报道可用于治疗晚期NETs。
•我们描述了一名患有侵袭性原发性卵巢NET的患者，用依维莫司（一种mTOR抑制剂）成功治疗。
相似文献
1
Aggressive neuroendocrine tumor of the ovary with multiple metastases treated with everolimus: A case report.
Gynecol Oncol Rep. 2018 Jan 4;23:20-23. doi: 10.1016/j.gore.2018.01.002. eCollection 2018 Feb.
2
Budget impact of everolimus for the treatment of progressive, well-differentiated, non-functional neuroendocrine tumors of gastrointestinal or lung origin that are advanced or metastatic.
J Med Econ. 2017 Apr;20(4):395-404. doi: 10.1080/13696998.2016.1273228. Epub 2017 Jan 4.
3
Efficacy and Safety of Everolimus in Extrapancreatic Neuroendocrine Tumor: A Comprehensive Review of Literature.
Oncologist. 2016 Jul;21(7):875-86. doi: 10.1634/theoncologist.2015-0420. Epub 2016 Apr 6.
4
Multiple ulcers and perforation of small intestine with everolimus use in a patient with rectal neuroendocrine tumor: A case report.
Int J Surg Case Rep. 2023 May;106:108094. doi: 10.1016/j.ijscr.2023.108094. Epub 2023 Mar 30.
5
Clinical Evaluation of Everolimus in the Treatment of Neuroendocrine Tumors of the Lung: Patient Selection and Special Considerations. A Systematic and Critical Review of the Literature.
Lung Cancer (Auckl). 2020 Jul 8;11:41-52. doi: 10.2147/LCTT.S249928. eCollection 2020.
6
Neuroendocrine tumors in the ovary: histogenesis, pathologic differentiation, and clinical presentation.
Arch Gynecol Obstet. 2016 Mar;293(3):659-65. doi: 10.1007/s00404-015-3865-0. Epub 2015 Aug 26.
7
Advances in the Diagnosis and Management of Well-Differentiated and Intermediate-Differentiated Neuroendocrine Tumors of the Lung.
Chest. 2017 May;151(5):1141-1146. doi: 10.1016/j.chest.2016.06.018. Epub 2016 Jun 29.
8
Phase II Study of BEZ235 versus Everolimus in Patients with Mammalian Target of Rapamycin Inhibitor-Naïve Advanced Pancreatic Neuroendocrine Tumors.
Oncologist. 2018 Jul;23(7):766-e90. doi: 10.1634/theoncologist.2017-0144. Epub 2017 Dec 14.
9
Everolimus, lutetium-177 DOTATATE and sunitinib for advanced, unresectable or metastatic neuroendocrine tumours with disease progression: a systematic review and cost-effectiveness analysis.
Health Technol Assess. 2018 Sep;22(49):1-326. doi: 10.3310/hta22490.
10
Everolimus and pancreatic neuroendocrine tumors (PNETs): Activity, resistance and how to overcome it.
Int J Surg. 2015 Sep;21 Suppl 1:S89-94. doi: 10.1016/j.ijsu.2015.06.064. Epub 2015 Jun 27.
引用本文的文献
1
A rare case report of primary ovarian carcinoid presenting with constipation.
Front Oncol. 2025 Feb 6;15:1489978. doi: 10.3389/fonc.2025.1489978. eCollection 2025.
2
Trastuzumab deruxtecan effectively controlled recurrent ovarian large-cell neuroendocrine carcinoma with low-level HER-2 expression: a case report.
Front Oncol. 2024 Jan 26;14:1339806. doi: 10.3389/fonc.2024.1339806. eCollection 2024.
3
A human pilot study on positive electrostatic charge effects in solid tumors of the late-stage metastatic patients.
Front Med (Lausanne). 2023 Oct 17;10:1195026. doi: 10.3389/fmed.2023.1195026. eCollection 2023.
4
A Young Iranian Woman with Pure Primary Ovarian Neuroendocrine Tumor: A Case Report.
Iran J Pathol. 2022 Summer;17(3):371-375. doi: 10.30699/IJP.2022.542788.2766. Epub 2021 Aug 14.
5
Incidence and Survival Rates for Female Malignant Germ Cell Tumors: An Institutional Review.
Cureus. 2022 Apr 26;14(4):e24497. doi: 10.7759/cureus.24497. eCollection 2022 Apr.
6
Neuroendocrine neoplasms of the ovary: an analysis of clinicopathological characteristics and prognosis with a focus on histological grading.
Endocrine. 2022 Jun;77(1):188-198. doi: 10.1007/s12020-022-03067-y. Epub 2022 May 11.
7
Emerging Therapeutic Concepts and Latest Diagnostic Advancements Regarding Neuroendocrine Tumors of the Gynecologic Tract.
Medicina (Kaunas). 2021 Dec 7;57(12):1338. doi: 10.3390/medicina57121338.
8
Therapeutic Management of Rare Primary Ovarian Neoplasms: Carcinosarcoma, Leiomyosarcoma, Melanoma and Carcinoid.
Int J Environ Res Public Health. 2021 Jul 23;18(15):7819. doi: 10.3390/ijerph18157819.
9
Mixed Large Cell Neuroendocrine Carcinoma of the Ovary: Report of a Rare Case.
Case Rep Obstet Gynecol. 2020 Nov 25;2020:8896070. doi: 10.1155/2020/8896070. eCollection 2020.
10
Primary ovarian carcinoid: Two cases report and review of literature.
Medicine (Baltimore). 2020 Oct 2;99(40):e21109. doi: 10.1097/MD.0000000000021109.
本文引用的文献
1
Treatment Strategies for Metastatic Neuroendocrine Tumors of the Gastrointestinal Tract.
Curr Treat Options Oncol. 2017 Mar;18(3):14. doi: 10.1007/s11864-017-0461-5.
2
Chemoembolization of Neuroendocrine Liver Metastases Using Streptozocin and Tris-acryl Microspheres: Embozar (EMBOsphere + ZAnosaR) Study.
Cardiovasc Intervent Radiol. 2017 Mar;40(3):394-400. doi: 10.1007/s00270-016-1535-7. Epub 2016 Dec 29.
3
High-grade Neuroendocrine Carcinoma of the Lung With Carcinoid Morphology: A Study of 12 Cases.
Am J Surg Pathol. 2017 Feb;41(2):263-270. doi: 10.1097/PAS.0000000000000767.
4
Neuroendocrine tumors in the ovary: histogenesis, pathologic differentiation, and clinical presentation.
Arch Gynecol Obstet. 2016 Mar;293(3):659-65. doi: 10.1007/s00404-015-3865-0. Epub 2015 Aug 26.
5
Primary ovarian carcinoid tumor showing unusual histology and nuclear accumulation of β-catenin.
Int J Clin Exp Pathol. 2015 May 1;8(5):5749-52. eCollection 2015.
6
Gynecologic Cancer InterGroup (GCIG) consensus review for carcinoid tumors of the ovary.
Int J Gynecol Cancer. 2014 Nov;24(9 Suppl 3):S35-41. doi: 10.1097/IGC.0000000000000265.
7
Targeting the mTOR signaling pathway in neuroendocrine tumors.
Curr Treat Options Oncol. 2014 Sep;15(3):365-79. doi: 10.1007/s11864-014-0294-4.
8
CDX2 may be a useful marker to distinguish primary ovarian carcinoid from gastrointestinal metastatic carcinoids to the ovary.
Hum Pathol. 2013 Nov;44(11):2536-41. doi: 10.1016/j.humpath.2013.06.014. Epub 2013 Sep 9.
9
A case of early-stage ovarian carcinoid tumor metastasized to the liver.
Case Rep Obstet Gynecol. 2012;2012:961087. doi: 10.1155/2012/961087. Epub 2012 Dec 26.
10
Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study.
Lancet. 2011 Dec 10;378(9808):2005-2012. doi: 10.1016/S0140-6736(11)61742-X. Epub 2011 Nov 25.
Zotero 插件